NCT00529035View on ClinicalTrials.gov

Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

June 30, 2011

Study Completion Date

May 27, 2020

Conditions
Graft Versus Host Disease
Interventions
DRUG

Interleukin-2

Dose will vary depending upon when participant enters the trial: Given as a daily injection under the skin for 8 weeks.

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Novartis

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT00529035 - Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease | Biotech Hunter | Biotech Hunter